Monitor the next quarter's revenue and adjusted EPS for continued momentum in high-value products and GLP-1 demand, which are key drivers of the raised guidance.
How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Apr 23 $307.95entry
- T+1 · 7mo ago −0.66%α −1.45% · $305.91
- T+5 · 7mo ago −4.09%α −5.57% · $295.36
- T+20 · 6mo ago −0.80%α −5.43% · $305.50
- T+60 · 4mo ago +16.33%α +11.41% · $358.24
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
West Pharmaceutical Services reported strong Q1 2026 results with revenue of $844.9M (+21.0% YoY) and adjusted EPS of $2.13 (+46.9% YoY), significantly beating consensus. The company raised its full-year 2026 revenue guidance to $3.295B-$3.350B and adjusted EPS guidance to $8.40-$8.75, driven by strong organic growth in high-value products and GLP-1 demand.
Key Financial Metrics
Key Facts
- Q1 2026 revenue: $844.9M, +21.0% YoY (+15.3% organic)
- Q1 2026 adjusted EPS: $2.13, +46.9% YoY
- Raised full-year 2026 revenue guidance to $3.295B-$3.350B (from $3.215B-$3.275B)
- Raised full-year 2026 adjusted EPS guidance to $8.40-$8.75 (from $7.85-$8.20)
- Repurchased 1.2M shares for $297.6M during Q1
Financial Impact
$844.9M revenue, $2.13 adjusted EPS
Risk Factors
- Currency fluctuations could impact reported revenue growth
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0000105770-26-000047 |
| Document: wst-20260423.htm | 0000105770-26-000047 |
| Document: a1q26earningsdeck-final.htm | 0000105770-26-000047 |
| Document: 0000105770-26-000047-index-headers.html | 0000105770-26-000047 |
| Document: 0000105770-26-000047-index.html | 0000105770-26-000047 |
| Document: 0000105770-26-000047.txt | 0000105770-26-000047 |
| 8-K Data (Synthetic) | 0000105770-26-000047 |
Track record
17 reports on WST
The track record builds as more bullish or bearish reports settle.
Filters
- Nov 5, 202611d ago SC 13G/A Neutral 2/10 Entry $392.48 Now $417.80 +6.45% settles Feb 3
- Oct 29, 202618d ago 8-K Bullish 6/10 No price data
- Oct 29, 202618d ago Press Release Bullish 6/10 Entry $416.67 Now $417.80 +0.27% settles Jan 27
- Oct 26, 202621d ago 8-K Neutral 4/10 Entry $398.29 Now $417.80 +4.90% settles Jan 25
- Oct 26, 202621d ago Institutional Cluster Neutral 3/10 Entry $394.73 Now $417.80 +5.84% settles Jan 22
- Jul 23, 202616w ago 8-K Bullish 7/10 No price data
- Jul 23, 202616w ago Press Release Bullish 7/10 Entry $355.48 to $383.02 Now $417.80 +17.53% ▲ +7.75% +3.19% vs SPY
- Jul 7, 202618w ago Press Release Neutral 1/10 Entry $356.08 to $370.76 Now $417.80 +17.33% ▲ +4.12% +2.13% vs SPY
- May 11, 202627w ago 8-K Bearish 7/10 Entry $311.82 to $348.06 Now $417.80 −33.99% ▼ −11.62% −7.51% vs SPY
- Apr 27, 202629w ago Insider Cluster Neutral 2/10 Entry $300.93 to $358.41 Now $417.80 +38.83% ▲ +19.10% +14.59% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers